Asia Pacific HPV Testing And Pap Test Market

APAC HPV Testing and Pap Test Market Size (2022 to 2027)

The HPV Testing and Pap Test Market size in the Asia Pacific was around USD 0.63 million in 2022. It is expected to grow at a CAGR of 6.7% to reach USD 0.87 million by 2027. It captures 15% of the global market.

The increasing incidence of infectious diseases in developing nations of Asia Pacific countries and growing awareness in people through the governments' various campaigns regarding the early cancer examination is majorly supporting the market's growth in this region. Rapid developments in the healthcare industry and the growing number of cancer cases in this region are further significant to the Asia-Pacific HPV Testing and Pap Test Market.

The escalating number of cervical cases is a positive sign of the growth rate of the market. For instance, in February 2014, Qiagen introduced the careHPV test in India, and the invention of this novel diagnostic examination is projected to enlarge the protective screening measures opposing cervical cancer. Furthermore, growth in the number of hospital construction, increasing developments in the early diagnosis of the diseases are also contributing to the growth of the market.

Unfavorable reimbursement policies are expected to hinder the growth of the HPV testing and PAP test market in the Asia-Pacific to a small extent.

This research report on the Asia Pacific HPV Testing and Pap Test Market has been segmented and sub-segmented into the following categories:

By Test Type:

• HPV Testing
• Follow-up HPV Testing
• HPV Primary Testing
• Co-Testing
• PAP Test

By Application:

• Vaginal Cancer Screening
• Cervical Cancer Screening

By End-users:

• Laboratories
• Hospitals
• Physicians
• Offices
• Clinics

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, it is the third-largest market in terms of market share and second largest in terms of CAGR. China is the leading market in this region due to the rising old age people population; a rise in the healthcare sector and increasing applications from existing nations will further accelerate the opportunities leading to the growth of the HPV and PAP test market in the region.

Indian HPV testing and PAP test market is expected to be more lucrative during the forecast period. The Indian government has taken a few measures generalizing examination programs, which is estimated to flourish the market growth in the region throughout the assessment period. Increase in R & D investments for inventing products and technologies augmenting the market growth in the area.

Notable companies dominating the Asia Pacific HPV Testing and PAP Test Market profiled in this report are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.